ā† Back to Search

Device Modification

Speech Processor Programming for Single-Sided Deafness with Cochlear Implant

N/A
Recruiting
Led By Jill B Firszt, PhD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial is testing whether reducing interaural mismatches (differences in loudness and pitch between the ears) through speech processor program modifications will improve speech understanding in noise and localization for people with SSD-CI.

Who is the study for?
This trial is for adults over 18 with single-sided deafness (SSD) who have normal hearing in one ear and are either experienced users of a Nucleus cochlear implant or will be newly implanted. They must have had postlingual onset of SSD, meaning they became deaf after having learned to speak.Check my eligibility
What is being tested?
The study tests modifications to the speech processor program of cochlear implants in individuals with SSD. The goal is to improve binaural cues which help with understanding speech in noisy environments and sound localization by reducing loudness and pitch differences perceived between ears.See study design
What are the potential side effects?
Since this trial involves non-invasive programming adjustments to existing cochlear implants, direct physical side effects are not anticipated. However, changes may affect auditory comfort or perception during the adjustment period.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Speech

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
CI speech processor programming

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,933 Previous Clinical Trials
2,299,675 Total Patients Enrolled
CochlearIndustry Sponsor
89 Previous Clinical Trials
5,981 Total Patients Enrolled
Jill B Firszt, PhDPrincipal InvestigatorWashington University School of Medicine
3 Previous Clinical Trials
179 Total Patients Enrolled

Media Library

Treatment-modifications to CI speech processor program (Device Modification) Clinical Trial Eligibility Overview. Trial Name: NCT05494632 ā€” N/A
Outcomes Research Study Groups: Single arm
Outcomes Clinical Trial 2023: Treatment-modifications to CI speech processor program Highlights & Side Effects. Trial Name: NCT05494632 ā€” N/A
Treatment-modifications to CI speech processor program (Device Modification) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05494632 ā€” N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are enrolled in this trial currently?

"Affirmative. As per clinicaltrials.gov, this medical study is actively recruiting patients and has been since August 8th, 2022; the last update to its information was also on that date. The trial seeks 50 participants from one location."

Answered by AI

Are there any opportunities still available to join this clinical exploration?

"Affirmative. Clinicaltrials.gov records show that this trial is actively recruiting with an initial post date of August 8th 2022 and a last updated on the same day. Approximately 50 participants must be recruited from 1 site for successful completion of the study."

Answered by AI
~7 spots leftby Aug 2024